Cencora, Inc. (COR)

FairStock Score: 43/100 — MIXED

Key Financials

Strengths

• Essential healthcare distribution business with predictable, recurring revenues
• Strong free cash flow generation of $3.5B annually
• Market consolidation provides pricing power and scale advantages
• Low beta (0.65) indicates defensive characteristics in market downturns
• Established competitive moat through customer relationships and scale

Concerns

• Severely overvalued with 39.2x P/E and Graham Number suggesting 1,321% overpricing
• Razor-thin profit margins (0.65%) indicate commoditized business with limited pricing power
• High leverage at 4.73 D/E ratio amplifies financial risk and inflates ROE artificially
• Weak Piotroski F-Score (5/9) and concerning Altman Z-Score (1.74) signal financial deterioration
• EV/EBITDA of 71.18 is excessive for a low-growth distribution business

AI Analysis

I'm examining Cencora with considerable skepticism. At $358.46, this medical distributor trades at 39.2x earnings with a Graham Number of just $25.21—suggesting a margin of safety of negative 1,321%. That's not margin of safety; that's a margin of folly. The business itself possesses legitimate qualities: it operates in an essential sector with predictable demand, boasts a 0.65 beta indicating stability, and generated $3.5B in free cash flow. The 133% ROE appears impressive until you examine the capital structure—a 4.73 debt-to-equity ratio inflates returns artificially. Most troubling is the Piotroski F-Score of 5/9 and Altman Z-Score of 1.74, both signaling financial distress. The EV/EBITDA multiple of 71.18 is absurdly elevated for a low-margin distributor. Yes, Cencora benefits from consolidation in healthcare distribution and has pricing power through scale, but these advantages are fully—indeed, excessively—priced in. The latest quarter's 0.65% net margin reveals the commoditized nature of pharmaceutical distribution. While free cash flow remains positive, the negative FCF yield suggests the business isn't growing fast enough to justify current valuations. This is a quality business trading at a reckless price. I'd rather wait for a genuine market correction or find comparable distribution businesses at sensible valuations.

Bull Case

Cencora's dominance in pharmaceutical distribution positions it to benefit from aging demographics and increased healthcare spending. The company's scale advantages create durable competitive moats, and consistent free cash flow supports shareholder returns. As healthcare consolidates further, Cencora's essential role strengthens.

Bear Case

The valuation is indefensible—trading at nearly 40x earnings for a low-margin, slow-growth distributor with deteriorating financial metrics. Debt-fueled buybacks inflate returns while actual operational performance weakens. A market correction or competitive disruption could trigger a significant reset lower.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer